Astellas Pharma Inc

Discover how Astellas Pharma’s ASCO 2026 strategy could reshape oncology, prostate care, and women’s health—unpacking data, risks, and investor impact.

Read how Astellas Pharma’s record Q4 2026 sales, new generics and biosimilar launches drive growth, and its FY2027 strategy for expanding respiratory, metabolic and oncology pipelines.

Stewart Williams joins Astellas Pharma’s board, bringing proven digital and operational transformation expertise to accelerate value‑based reimbursement, cut costs, and boost profitability in a complex healthcare market.

Astellas Pharma’s settlement with MSN allows a generic Myrbetriq launch while securing steady royalties, boosting cash flow and supporting its regenerative‑medicine focus.

Discover how Astellas Pharma’s 2023 earnings surge, 11 % revenue growth and R&D focus signal strong future momentum despite market dips.

Explore Astellas’ first‑in‑class TROP2‑targeted iADC ASP2998, combining dual cytotoxic payloads with a STING agonist to turn cold tumours hot and reshape oncology’s ADC future.

Explore how Astellas Pharma’s new precision‑medicine focus on rare kidney disease (ADPKD) and hormone‑receptor‑positive breast cancer is reshaping its oncology and nephrology pipelines, driving biologic innovation and market growth.

Explore how Astellas Pharma and Vir Biotechnology’s new PSMA‑targeting bispecific T‑cell engager could change advanced prostate cancer treatment, detailing science, trials, and regulatory strategy.

Discover how Astellas Pharma’s strategic shift to a higher‑priced public offering boosts capital efficiency, supports AI‑driven drug development, and strengthens shareholder value in the biopharma sector.

Discover how Astellas and Vir Biotechnology’s global partnership for VIR‑5500 could transform prostate‑cancer treatment, blending advanced immunotherapy with strategic market‑access plans.